Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

SCHOTT Doubles its Production Capacity for SCHOTT TopPac® Polymer Syringes

Published: Tuesday, April 30, 2013
Last Updated: Monday, April 29, 2013
Bookmark and Share
Company to offer customers a greater degree of flexibility and ensure supply security.

To address the increasing global demand for prefillable polymer syringes, SCHOTT is currently expanding its manufacturing capacity for small size (1 to 10 ml) SCHOTT TopPac® syringes.

A new production line installed at the SCHOTT site in St. Gallen, Switzerland, expanded the existing production capacity by 100% from April onwards.

This enables SCHOTT to offer customers a greater degree of flexibility and ensure supply security.

SCHOTT is a pioneer in establishing the SCHOTT TopPac® product range as ready-to-fill syringes, which are made of Cyclic Olefin Copolymer (COC).

Over the past 15 years, SCHOTT made significant investments to develop and industrialize COC material for pharmaceutical containers for injectable drugs.

COC is an inert material and the SCHOTT TopPac® syringe system is designed to be compatible with a broad range of drugs. The excellent barrier properties of the SCHOTT TopPac® syringe system allow long term storage of drugs even in small syringe sizes.

In addition, SCHOTT TopPac® syringes have a glass-like transparency, and are break resistant and lightweight.

SCHOTT TopPac® syringes are available in the range from 1ml to 50ml with cross linked silicone for optimal functionality.

Pharmaceutical companies benefit from the fact that SCHOTT TopPac® syringes are manufactured in clean rooms with a fully automated process starting from injection-molding to the final packaging in nest and tub. The syringes are sterilized and are ready for aseptic filling operations.

SCHOTT intends to achieve further growth in the field of polymer and glass syringes and also underscores its commitment to offer ideal product solutions to pharmaceutical companies - today and tomorrow.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Announces Major Expansion of Pharmaceutical Packaging Manufacturing in Russia
Capacity to expand by more than 50 percent / Consistent investment strategy helps customers achieve growth and quality objectives.
Monday, November 26, 2012
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos